ReachMD CME

ReachMD
  • 4.3 (3)
  • SCIENCE
  • UPDATED MONTHLY
ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

  1. 17H AGO

    Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF

    CME credits: 1.50 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/factoring-solutions-to-the-management-of-stroke-care-in-the-settings-of-secondary-prevention-and-af/29099/ Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-risk profile of anticoagulation therapies. Learn how these therapies may impact the prevention of ischemic stroke and secondary stroke in patients with atrial fibrillation. =

  2. 1D AGO

    Personalizing Care Within the RCC Treatment Paradigm

    CME credits: 1.00 Valid until: 13-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-care-within-the-rcc-treatment-paradigm/29528/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores the latest advances in risk stratification and evidence-based approaches for managing advanced renal cell carcinoma (RCC). Participants will gain a deeper understanding of guideline-driven treatment strategies across RCC histologies and learn strategies for the integration of multidisciplinary approaches to optimize patient care. Emphasis will be placed on shared decision-making and innovative solutions for monitoring and managing treatment-related adverse events. Learners will gain actionable insights for personalizing RCC care and improving patient outcomes. =

  3. JAN 31

    No Patient Left Behind! Advancing CKD-Associated Pruritus Care

    CME credits: 0.25 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-left-behind-advancing-ckd-associated-pruritus-care/26637/ Patients with chronic kidney disease-associated pruritus (CKD-aP) often face delays in diagnosis and treatment, as well as potential side effects from some prescribed medicines. Tune in as our experts dive into the burden of CKD-aP symptoms and break down the long-term outcomes and benefits of new and emerging treatments. =

  4. JAN 23

    Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies

    CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

  5. JAN 23

    Emerging data with potentially guideline-changing implications in CLL/SLL and MCL

    CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-with-potentially-guideline-changing-implications-in-cllsll-and-mcl/32287/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

  6. JAN 23

    Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor

    CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

  7. JAN 23

    Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy

    CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

  8. JAN 17

    Autoantibodies in MG: Their Role in Diagnosis and Treatment

    CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

See All (470)

    Ratings & Reviews

    4.3
    out of 5
    3 Ratings

    About

    Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

    Information

    • Creator
      ReachMD
    • Years Active
      2015 - 2025
    • Episodes
      470
    • Rating
      Clean
    • Copyright
      © Copyright 2025 ReachMD. All rights reserved.
    • Show Website
      ReachMD CME

    Content Restricted

    This episode can’t be played on the web in your country or region.

    To listen to explicit episodes, sign in.

    Stay up to date with this show

    Sign in or sign up to follow shows, save episodes, and get the latest updates.
    Select a country or region

    Africa, Middle East, and India

    Asia Pacific

    Europe

    Latin America and the Caribbean

    The United States and Canada